Sanofi SA $ 49.69 0.05 (0.1%)
Volume:
3,099,143
Avg Vol (1m):
2,111,769
Market Cap $:
124.86 Bil
Enterprise Value $:
135.99 Bil
P/E (TTM):
9.29
P/B:
1.62
Financial Strength | 6/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 0.64 | ||
Equity-to-Asset | 0.55 | ||
Debt-to-Equity | 0.39 | ||
Debt-to-EBITDA | 1.39 | ||
Interest Coverage | 19.22 | ||
Piotroski F-Score | 6 | ||
Altman Z-Score | 1.67 | ||
Beneish M-Score | -2.49 | ||
WACC vs ROIC |
Profitability Rank | 7/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | 20.3 | ||
Net Margin % | 29.28 | ||
ROE % | 18.54 | ||
ROA % | 9.76 | ||
ROC (Joel Greenblatt) % | 88.26 | ||
3-Year Revenue Growth Rate | 3.8 | ||
3-Year EBITDA Growth Rate | 3.7 | ||
3-Year EPS without NRI Growth Rate | -12 |
Valuation Rank | 8/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
PE Ratio | 9.29 | ||
Forward PE Ratio | 12.69 | ||
PE Ratio without NRI | 9.2 | ||
Price-to-Owner-Earnings | 16.19 | ||
PB Ratio | 1.62 | ||
PS Ratio | 2.72 | ||
Price-to-Free-Cash-Flow | 14.99 | ||
Price-to-Operating-Cash-Flow | 12.07 | ||
EV-to-EBIT | 9.14 | ||
EV-to-EBITDA | 6.23 | ||
EV-to-Revenue | 2.96 | ||
PEG Ratio | 16.76 | ||
Shiller PE Ratio | 20.78 | ||
Current Ratio | 1.85 | ||
Quick Ratio | 1.38 | ||
Days Inventory | 253.8 | ||
Days Sales Outstanding | 69.75 | ||
Days Payable | 148 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
Dividend Yield % | 3.42 | ||
Dividend Payout Ratio | 0.35 | ||
3-Year Dividend Growth Rate | 1.6 | ||
Forward Dividend Yield % | 3.42 | ||
5-Year Yield-on-Cost % | 3.77 | ||
3-Year Average Share Buyback Ratio | 0.5 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 99.38 | ||
Price-to-Intrinsic-Value-Projected-FCF | 1.02 | ||
Price-to-Median-PS-Value | 1 | ||
Price-to-Graham-Number | 6.38 | ||
Earnings Yield (Greenblatt) % | 10.94 | ||
Forward Rate of Return (Yacktman) % | 7.37 |